WP5 Strand A – Procedure Manual V 4
This document describes processes planned for conducting pilot rapid assessments for pharmaceuticals. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. 2012123627 – Procedure_manual_REA pilots_WP5_Strand A
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment (Core HTA 2)
The Core HTA is available online at the Core Model Online Tool here. Relevant document can be found as a pdf below. The aim of this core HTA was to compare Immunoglobulins (IGG) to placebo, not doing anything or Usual supportive care in the treatment of Alzheimer’s disease in elderly. Agenas, Italy is the editor […]
Training course for all EUnetHTA Stakeholders, Apr. 23rd, 2015
Presentations from the 3rd face to face training course for EUnetHTA Stakeholders organised by JA2WP2; April 23rd, Brussels. Brief introduction to EUnetHTA and its Tools, Marianne Klemp, NOKC The HTA Core Model® A brief introduction, Anna Nachtnebel, LBI-HTA How to use HTA for decision-making based on HTA Core Information, Anna Nachtnebel, LBI-HTA, Simone Warren, ZIN […]
The 5th pilot rapid assessment of WP5 JA2 Strand B on “Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation” is now available.
The purpose of the assessment is to address the research question whether the use of the technologies in question is more effective and/or safer than their comparators, which were chosen based on CE mark indications, recommendations in clinical guidelines for the treatment of MR and EUnetHTA guidelines. Final version of the assessment was published in […]
Structured telephone support (STS) for adult patients with chronic heart failure (Core HTA 3)
The aim of this core HTA was to compare Structured telephone support (STS) for adult patients with chronic heart failure compared to Usual care defined as regular schedules of visits of the patient at the heart center/ GP/cardiologist or patient has to move (≠ at home). Agenas, Italy is the editor of this joint assessment […]
Publication of a JA2 methodological guideline – Internal validity of non-randomised studies (NRS) on interventions
During Joint Action 1 a methodological guideline on internal validity of randomised studies (RCT) had been elaborated. It was recommended from different sides that EUnetHTA should also produce and consent a guidance document for the assessment of non-randomised studies. The new guideline has been developed by WP 7 to address this need. It contains a […]
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment Amended JA1 Guideline Final Nov 2015
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment_Amended JA1 Guideline_Final Nov 2015
Joint Assessment on Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)
The purpose of the assessment is to evaluate Vorapaxar (ZONTIVITY™) for the reduction of cardiovascular events. Final version of the assessment was published in June 2015 Below is the documentation provided by the Joint Assessment authoring team Vorapaxar for the reduction of thrombotic cardivascular events_Rapid REA_Final_Jun 2015
Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C”
The purpose of the assessment is to evaluate multiple new pharmaceuticals for the treatment of Chronic Hepatitis C. Final version of the assessment was published in December 2015 Below is the documentation provided by the Joint Assessment authoring team: WP5-SA6 Final Appendix Feedback Complete 17122015WP5-SA6 Final Appendix Content Complete Update January 2016WP5-SA6 Final Version of […]
Internal validity of non-randomised studies (NRS) on interventions Guideline Final Jul 2015
Internal validity of non-randomised studies (NRS) on interventions_Guideline_Final Jul 2015
